

FIRST PRENATAL VISIT (6 - 10 weeks)	11 - 14 WEEKS GESTATION	18 - 22 WEEKS GESTATION	GESTATIONAL DIABETES MELLITUS (GDM) * DCPNS 2021
<ul style="list-style-type: none"> Hemoglobin / Platelets ABO/Rh(D) and antibody screen Urine C&S Hepatitis B Antigen Syphilis serology HIV screen (considered standard of care; counsel and inform of risks/benefits of screen and the right of refusal). Rubella: screen if immune status is unknown. Vaccination advised post-partum if nonimmune. Varicella: screen if no history of infection, vaccination, or positive serology. Vaccination advised post-partum if non-immune. TSH / Serum Ferritin if indicated (see indications on back) GDM screen * Gonorrhea and chlamydia: screen if at risk (e.g. age < 25 years, previous STI's, new sexual partner, etc.) Cervical cytology if indicated (as per NS Cervical Screening Guidelines). 1st trimester dating U/S between 7-12 weeks (ideally) to confirm gestational age, viability, number of fetuses, early anatomic assessment, and chorionicity in multiples (plus or minus nuchal translucency (NT) as MST not applicable for multiples). Genetic risk screen: consult Maritime Medical Genetics (MMG) prn. 	<p>Cell Free DNA (NIPT)</p> <ul style="list-style-type: none"> Discuss NIPT with all pregnant persons; however it is provincially funded <u>only</u> for those with a high-risk screening result for Trisomy 21 in lieu of invasive testing. The testing will be offered to patients when they are seen by Maternal Fetal Medicine (MFM) or MMG and after being identified as high risk through maternal serum testing (MST). If a patient wants NIPT in lieu of standard screening, or after a low-risk screening result, the testing is available by self-pay through an independent referral laboratory. These patients should then not undertake any MST. <p>Early Maternal Serum Testing:</p> <ul style="list-style-type: none"> Offer early MST to all pregnant persons regardless of age. Note: 2nd trimester testing must be done along with 1st trimester testing for an integrated screen. <p>Early Pregnancy Review (EPR):</p> <ul style="list-style-type: none"> Offer to pregnant persons with specific risk factors and those > 35 years of age at the EDD. An EPR, conducted at the FATC at the IWK, is an ultrasound to review viability, dates, early development and assess for fetal abnormalities, through specific markers, particularly a nuchal translucency. An EPR is best used in conjunction with the MST for assessment of risk for Trisomy 21. 	<p>2nd trimester U/S</p> <ul style="list-style-type: none"> Offer to all pregnant persons. Includes fetal biometry, amniotic fluid volume, placentation, anatomical review for anomalies, and markers for fetal aneuploidy. 	<p>Screen everyone with a HbA1c with their prenatal bloodwork. Add fasting plasma glucose (FPG) for those with renal disease, a hemoglobinopathy, or strong risk factors (i.e. prediabetes, previous GDM, multiple gestation, BMI > 40 kg/m², PCOS, corticosteroid use, glycosuria, or high-risk population (Indigenous/First Nations, Hispanic, South Asia, Asian, African Canadian)).</p>
	14 - 22 WEEKS GESTATION	<p>2nd trimester MST:</p> <ul style="list-style-type: none"> Offer to all pregnant persons regardless of age. <p>Integrated Maternal Serum Test (IMST):</p> <ul style="list-style-type: none"> Incorporates maternal age and 1st and 2nd trimester MST into an integrated assessment of risk for fetal chromosomal abnormalities, open fetal defects, and placental abnormalities. <p>Integrated Prenatal test: IMST with EPR included in the integration.</p>	<p style="background-color: #e0f2f1; text-align: center;">24 - 28 WEEKS GESTATION</p> <ul style="list-style-type: none"> Hemoglobin / Platelets Repeat antibody screen <p>If Rh (D) Negative: Repeat antibody screen at 26-28 weeks BEFORE giving WinRho®SDF at 28 - 29⁺⁶ weeks. WinRho®SDF is not required if the baby's father is documented to be Rh(D) negative. Refer to Rh Guidelines</p> <ul style="list-style-type: none"> Syphilis serology HIV (re)screen if high risk GDM screen ** Tdap vaccine -27-32 weeks
		35-37 WEEKS GESTATION	24-28 WEEKS GDM SCREEN (PREFERRED) **
		<ul style="list-style-type: none"> Group B strep Gonorrhea and chlamydia <p style="background-color: #e0f2f1; text-align: center;">Complete EACH Trimester</p> <ul style="list-style-type: none"> EPDS (Anxiety / Depression screen) W-AST (Intimate partner violence (IPV) screen) TACE (Alcohol screen) 	<p>HbA1c plus or minus FPG</p> <ul style="list-style-type: none"> HbA1c ≥ 6.5% and/or FPG ≥ 7 mmol/L = overt diabetes or GDM* HbA1c ≥ 5.7% and/or FPG ≥ 5.3mmol/L = GDM* HbA1c < 5.7% and/or FPG < 5.3 mmol/L = lower risk for GDM, repeat screen at 24-28 weeks
			24-28 WEEKS GDM SCREEN (ALTERNATE) **
			<p>Random 50g 1-hour GCT</p> <ul style="list-style-type: none"> 1-hour VPG ≥ 11.1 mmol/L = GDM* 1-hour VPG < 7.8 mmol/L = no GDM 1-hour VPG 7.8 -11.0 mmol/L = proceed to 75-g OGTT. <ul style="list-style-type: none"> Fasting VPG ≥ 5.3 mmol/L = GDM* 1 hour ≥ 10.6 mmol/L = GDM* 2-hour ≥ 9 mmol/L = GDM*
			<p>HbA1c and FPG</p> <ul style="list-style-type: none"> HbA1c ≥ 5.7% and/or FPG ≥ 5.3mmol/L = GDM* HbA1c < 5.7% and/or FPG < 5.3 mmol/L = no GDM <p>* GDM diagnosis: No further testing required. Refer immediately to local specialty diabetes team for nutrition plan; physical activity; self-monitoring of blood glucose. Refer to GDM screening in NS</p>

Significant effort has been made to ensure the accuracy of information and to reflect best practice. Evidence and clinical care change rapidly. The information within does not indicate an exclusive course of action or standard of care and does not replace the need for clinical judgment, clinical advice, or individualized care recommendations. (April 2022)

PREECLAMPSIA: RISK FACTORS <small>NICE 2020</small>	PRETERM BIRTH: RISK FACTORS <small>NICE 2019 SOGC 2017</small>	INDICATIONS for ↑ FETAL SURVEILLANCE <small>ACOG 2014 SOGC 2018</small>	DISCUSSION TOPICS
<p>High Risk</p> <ul style="list-style-type: none"> Hypertensive disease in previous pregnancy Chronic kidney disease Systemic lupus erythematosus (SLE) Antiphospholipid antibody syndrome (APS) Type 1/2 diabetes Chronic hypertension <p>Moderate Risk</p> <ul style="list-style-type: none"> First pregnancy Age ≥ 40 years Pregnancy interval > 10 years BMI ≥ 35 kg/m² Family history of preeclampsia Multifetal pregnancy <p>Consult OBS if history of previous preeclampsia or strong clinical markers of ↑ risk of hypertension.</p> <ul style="list-style-type: none"> Establish GA, baseline BP, and lab values (e.g. creatinine, liver function, urinary protein creatinine ratio). Initiate low-dose aspirin (81-162 mg/day) starting before 16 weeks and stopping by 36 weeks for those with a high-risk factor for preeclampsia or with more than 1 moderate risk factor. <small>SOGC 2014/2021</small> Closely monitor BP and weight gain. Consider calcium supplements (1 gram / day) for those with low calcium intake. 	<ul style="list-style-type: none"> Previous preterm birth Cervical surgery Cervical insufficiency Uterine anomaly / surgery ART Poor nutrition Low socioeconomic status Abuse (IPV) Age < 17 or > 40 Physical labor + fFN 22 - 34 weeks Interpregnancy interval < 6 months Poly/Oligohydramnios BMI < 18 kg/m² Diabetes Hypo/hyper thyroid Black or Indigenous Mental illness < grade 12 education Substance use Poor prenatal care Infections Fetal anomaly Vaginal bleeding Multiple gestation Short cervical length P-PROM Periodontal disease <p>Consult OBS</p> <ul style="list-style-type: none"> Vaginal progesterone therapy (VPT) for those with a short cervical length in current pregnancy (≤ 25 mm by transvaginal U/S between 16 – 24 weeks) or with a previous PTB. Daily dose: 200 mg for single pregnancy / 400 mg for multiple pregnancy, initiated between 16–24 weeks gestation (whenever risk is identified). VPT can be continued up to 34–36 weeks gestation (considering individual risk factors). 	<p>Weekly at 32 weeks</p> <ul style="list-style-type: none"> Twins: MCDA Pre-existing diabetes: poor glycemic control SLE APS Sickle cell disease Renal/cardiac disease: unstable Rh Iso-immunization Previous 3rd trimester loss Previous IUGR or preeclampsia requiring preterm delivery Thrombophilia: high risk <p>1 to 2 times per week</p> <ul style="list-style-type: none"> IUGR (< 5th percentile) Post-term (> 41 weeks) Preeclampsia <p>ASAP and prn</p> <ul style="list-style-type: none"> ↓ fetal movement MVA <p>Consult OBS when increased fetal surveillance is indicated or if risk of fetal demise is identified and delivery for perinatal benefit would be considered.</p> <p>Indications for increased fetal surveillance are suggestions only. Individualization about when to offer antenatal fetal surveillance is advised.</p> <p>Weekly at 36 weeks</p> <ul style="list-style-type: none"> Twins: DCDA Pre-existing diabetes: good glycemic control Abnormal MST Renal/cardiac disease: stable ART BMI ≥ to 40 / Age > 40 GDM treated with insulin Thrombophilia: low risk Velamentous cord insertion Single umbilical artery Alcohol use (≥ 5 drinks/week) <p>Weekly from Dx</p> <ul style="list-style-type: none"> P-PROM Gestational hypertension Chronic abruption Oligohydramnios Polyhydramnios Cholestasis IUGR 	<ul style="list-style-type: none"> Vitamins / iron Nutrition counselling / GWG Food safety ID precautions (e.g. pets) Hot tubs / Saunas Seat belts / Air bags Course of care / emergency contact TOLAC counseling prn Physical / sexual activity Pelvic floor health Prenatal education / resources Immunization status Early pregnancy loss: signs and symptoms, what to do Signs of preterm labour / preeclampsia / P-PROM Work / parental Leave Fetal growth / movement Birth expectations: fears, family adjustment, support person(s) Late pregnancy symptoms Normal stages of labour / when to call care provider Pain relief options in labour Potential interventions / blood products Post-dates management / induction / cervical ripening Infant feeding plan Skin-to-skin / nursing Newborn care (e.g. vit K) Length of stay / discharge plan Postpartum contraception Postpartum depression
INDICATIONS for SERUM FERRITIN <small>UK Guideline 2019</small>	INDICATIONS for THYROID STIMULATING HORMONE (TSH) SCREEN <small>ACOG 2015 CADTH 2016</small>		
<p>Anemic: known haemoglobinopathy/prior IV iron replacement.</p> <p>Non-anemic with high risk of iron deficiency anemia: Previous anaemia; ≥ Para 3; Multiple pregnancy; Interpregnancy interval <1 year; poor dietary habits; vegetarian/vegan diet; Age < 20 years; recent history of clinically significant bleeding.</p> <p>Non-anemic when serum ferritin might be necessary: high risk of bleeding during pregnancy or at birth; those declining blood products; those whom providing compatible blood is challenging.</p>	<ul style="list-style-type: none"> + thyroid peroxidase Ab History of thyroid dysfunction Family history of thyroid disease S&S of thyroid dysfunction Recurrent miscarriages or PTB Infertility Goiter 	<ul style="list-style-type: none"> Age > 30 years Use of amiodarone / lithium / radiologic contrast Type 1 Diabetes Autoimmune disorder Resides in an area of moderate / severe iodine insufficiency 	<ul style="list-style-type: none"> BMI ≥ 40 Thyroid surgery Head or neck radiation <p style="background-color: #e0ffe0; padding: 2px;">TSH normal range (mU/L)</p> <p>1st Trimester: 0.1 - 2.5 2nd Trimester: 0.2 - 3.0 3rd Trimester: 0.3 - 3.0</p>

Significant effort has been made to ensure the accuracy of information and to reflect best practice. Evidence and clinical care change rapidly. The information within does not indicate an exclusive course of action or standard of care and does not replace the need for clinical judgment, clinical advice, or individualized care recommendations. (April 2022)